A coagulation-deficient tissue factor (TF) compound [e.g. IgG-H6-N'-cys-tTF219] that is at least 100 times less active than the native form and its use against vascular tumour

摘要

A composition comprising a biologically effective amount of a coagulation-deficient Tissue Factor compound that is at least about 100-fold less active than full length, native Tissue Factor and that has been modified to increase its biological half-life; wherein the modification does not consist of attaching the Tissue Factor compound to an antibody or antigen binding region thereof that binds to a diseased cell, a component of disease-associated vasculature or a component of disease-associated stroma. The administration of the composition results in the promotion of coagulation, preferentially, or specifically, in the prothrombotic blood vessels.